AT-46 VORINOSTAT AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMA: INTERIM ANALYSIS OF A PHASE II CLINICAL TRIAL

Prognosis for recurrent glioblastoma remains poor with progression-free survival at six months (PFS6) of 9-15%, but with the addition of bevacizumab, a monoclonal antibody to vascular endothelial growth factor-A (VEGF-A), studies have shown PFS6 improved to 40-50%. Vorinostat, a small molecule inhib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Peters, Katherine, Reardon, David, Randazzo, Dina, Dutton, Shelley, Edwards, Ashley, Lipp, Eric, Herndon, James, McSherry, Frances, Desjardins, Annick, Ranjan, Tulika, Vlahovic, Gordana, Friedman, Henry
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Adult Clinical Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217825/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.45
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados